Epigenetics and epigenomics is one of the most rapidly expanding fields in understanding the biology of cancer. Epigenetic changes play a role in cancer initiation, development, and progression/evolution. Epigenetic targets can be used to create a new generation of therapeutics in the setting of clinical trials.
Assessing the effectiveness of therapeutics requires the ability to measure quantitative epigenetic modifications. Technological advancements have made it possible to undertake genome-wide epigenomic studies to enable physicians and researches to examine disease pathology in systematic and comprehensive ways.
The goals of the Epigenomics Core Facility are:
- to integrate and make multiple technological platforms available for physicians and researchers
- to assist investigators in implementing targeted measurements of epigenetic modifications
- to develop novel reagents applicable for detection of epigenetic modification, in collaboration with individual researchers
The Hematologic Oncology Tissue Bank (HOTB) is a centralized, comprehensive resource for banking of human biological specimens to support research using primary human cells and tissue. This facility provides appropriate cell- and tissue-based specimens from patients with hematologic malignancies for investigator-initiated experimentation. Materials are also available from healthy volunteers for comparison.
The HOTB is housed within the Division of Hematologic Oncology in the Department of Medicine under the Director of James Young, but our resources are available to all Memorial Sloan Kettering investigators. The HOTB facilitates and optimizes the use of human biological specimen samples for research while protecting patients’ rights through an Institutional Review Board–sanctioned biospecimen collection protocol and informed consent process.